On Tuesday, Health Canada published a circular asking physicians to stop prescribing an obscure drug, Tavneos (avacopan), to new patients. We probably don’t have very many readers who are taking avacopan: it’s a drug approved recently (autumn 2021 in the U.S., spring of 2022 in Canada) for treatment of a rare and poorly understood autoimmune condition called “ANCA-associated vasculitis.” In western countries this disorder afflicts 10 or 20 persons per million a year, usually elderly ones. The symptoms, caused by out-of-control antibodies killing off interior blood vessels, range from “feeling poorly” to “choreographed and hasty organ failure.” Read More



Source link